title: Pharmacologic therapy of non-alcoholic steatohepatitis.
abstract: Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.
authors.affiliation: Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, 47-83 Bd de l'Hôpital, Paris 75013, France. vratziu@teaser.fr
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
authors.forename: Shira
authors.initials: S
authors.lastname: Zelber-Sagi
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001622:Betaine / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005234:Fatty Liver / Q000188:drug therapy* / Q000517:prevention & control; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D008082:Lipotropic Agents / Q000627:therapeutic use; D000077403:Orlistat; D010431:Pentoxifylline / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D024505:Tocopherols / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D019440:Anti-Obesity Agents; D000975:Antioxidants; D002756:Cholagogues and Choleretics; D016166:Free Radical Scavengers; D007783:Lactones; D008082:Lipotropic Agents; D045162:Thiazolidinediones; D001622:Betaine; D014580:Ursodeoxycholic Acid; D000077403:Orlistat; D011341:Probucol; D024505:Tocopherols; D010431:Pentoxifylline